Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

OS Therapies Incorporated Common Stock (NY: OSTX )

1.890 UNCHANGED
Streaming Delayed Price Updated: 8:00 PM EST, Feb 20, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 6
Open 1.890
Bid (Size) 1.790 (1)
Ask (Size) 1.890 (1)
Prev. Close 1.890
Today's Range 1.890 - 1.890
52wk Range 1.580 - 7.000
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
OS Therapies Receives Patent Notice of Allowance from U.S. Patent & Trademark Office Covering Commercial Manufacturing of OST-HER2
From OS Therapies, Inc.
Via Business Wire
Optimism in War on Cancer on the Rise, as Biotech Companies Roll Out More Wins
Vancouver, BC – February 18, 2025 – USA News Group News Commentary – Despite optimism coming from the launch of Project Stargate (a $500 billion investment in AI data centers), there is still cause for... 
Via FinancialNewsMedia
Topics Artificial Intelligence
Exposures Artificial Intelligence

Performance

YTD
-54.78%
-54.78%
1 Month
-39.42%
-39.42%
3 Month
+1.78%
+1.78%
6 Month
-52.99%
-52.99%
1 Year
-24.70%
-24.70%

More News

Read More
Small-Cap OS Therapies Inks Commercial Manufacture Agreements For Lead Cancer Drug For Rare Type Of Bone Cancer
Via Benzinga
Exposures Product Safety
Friday's session: gap up and gap down stocks
Via Chartmill
Top movers in Friday's pre-market session
Via Chartmill
OS Therapies Initiates Commercial-ready Manufacturing of OST-HER2 to Support Anticipated Biologics Licensing Authorization (BLA) Filing
From OS Therapies, Inc.
Via Business Wire
OS Therapies Provides Corporate Update
From OS Therapies, Inc.
Via Business Wire
RedChip Launches RedChat: Revolutionary AI Chatbot for Small-Cap Stock Analysis
Via ACCESS Newswire
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
OS Therapies Agrees to Acquire All Listeria Monotygenes-based Immuno-Oncology Programs and IP Assets from Ayala Pharmaceuticals, Adding Phase 2 Lung Cancer and Phase 1 Prostate Cancer Programs to Pipeline
From OS Therapies
Via Business Wire
Kairos, OS Therapies, AEON See Highest Weekly Spike In Retail Following Among Biotechs: Here's Why
Via Stocktwits
Exposures Product Safety
Why Is Pediatric-Cancer Focused OS Therapies Stock Trading Higher On Wednesday?
Via Benzinga
OS Therapies Announces Phase 2b Clinical Trial of OST-HER2 Achieves Primary Endpoint with Statistical Significance in the Prevention of Recurrent, Fully Resected, Lung Metastatic Osteosarcoma
From OS Therapies, Inc.
Via Business Wire
OS Therapies to Attend the 43rd Annual J.P. Morgan Healthcare Conference
From OS Therapies, Inc.
Via Business Wire
OS Therapies Announces Closing of $6 Million Private Placement
From OS Therapies, Inc.
Via Business Wire
OS Therapies Partners with B2i Digital to Engage with Biotech Investors Online
From OS Therapies, Inc.
Via Business Wire
OS Therapies Announces Pricing of $6 Million Private Placement
From OS Therapies, Inc.
Via Business Wire
OS Therapies Reports Third Quarter 2024 Financial Results and Provides Business Update
From OS Therapies, Inc.
Via Business Wire
OS Therapies to Present at The Spartan Capital Investor Conference
From OS Therapies
Via Business Wire
Join OS Therapies’ Exclusive Live Investor Webinar and Q&A Session on October 30
From OS Therapies
Via Business Wire
OS Therapies Appoints Two Bio-Pharmaceutical Industry Veterans to the Board of Directors
From OS Therapies
Via Business Wire
OS Therapies to Present at the LD Micro Main Event XVII
From OS Therapies
Via Business Wire
OS Therapies to Participate in a Fireside Chat at the 2024 Maxim Healthcare Virtual Summit
From OS Therapies
Via Business Wire
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
OS Therapies Announces Last Patient Enrolled in OST-HER2 Osteosarcoma Phase 2b Clinical Trial Completes Last Patient Visit
From OS Therapies
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.